Figure 3.
Figure 3. AMD3100 inhibits TCR-initiated production of IL-2, IL-4, and IL-10. Human PBMC T cells were treated with 60 μM AMD3100 for 1 hour and stimulated with plate-bound OKT3 and soluble CD28 as in Figure 1 for 24 hours. (A) Graphs summarize cytokine production assayed via ELISA from 9 donors, with the black line denoting the average of all donors tested ± SEM. *Significant difference compared with control cells (P < .05). (B-F) Following stimulation, cells were stained for CD3, CD4, CD45RO, and the indicated intracellular cytokine and analyzed by flow cytometry. Graphs summarize results from 5 donors, with the black line denoting the average of all donors tested ± SEM. *Significant difference compared with control cells (P < .05). FSC, forward scatter.

AMD3100 inhibits TCR-initiated production of IL-2, IL-4, and IL-10. Human PBMC T cells were treated with 60 μM AMD3100 for 1 hour and stimulated with plate-bound OKT3 and soluble CD28 as in Figure 1 for 24 hours. (A) Graphs summarize cytokine production assayed via ELISA from 9 donors, with the black line denoting the average of all donors tested ± SEM. *Significant difference compared with control cells (P < .05). (B-F) Following stimulation, cells were stained for CD3, CD4, CD45RO, and the indicated intracellular cytokine and analyzed by flow cytometry. Graphs summarize results from 5 donors, with the black line denoting the average of all donors tested ± SEM. *Significant difference compared with control cells (P < .05). FSC, forward scatter.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal